SEC Form 4 · accession 0001144204-17-032552
KIORA PHARMACEUTICALS INC · KPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen From
Officer — President and CEO · Director
Period of report
Jun 14, 2017
Accepted (ET)
Jun 14, 2017 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001372514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 14, 2017 | P$0 | 60,000 | — | A | 259,965 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants (right to buy)F1 | $1.50 | Jun 14, 2017 | P | 60,000 | A | Jun 14, 2017 | Jun 14, 2022 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1The reported securities were purchased by the reporting person for a combined purchase price of $1.50 per share of common stock and warrant in connection with the Issuer's public offering that closed on June 14, 2017. Each warrant will be exercisable during the period commencing on June 14, 2017 and ending on June 14, 2022 at an exercise price of $1.50.